The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
- 22 November 2023
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (12) , 1833-1851
Abstract
Opinion statement Given the considerable heterogeneity in neuroendocrine neoplasms (NENs), it appears unlikely that a sole biomarker exists capable of fully capturing all useful clinical aspects of these tumors. This is reflected in the abundant number of biomarkers presently available for the diagnosis, prognosis, and monitoring of NEN patients. Although assessment of immunohistochemical and radiological markers remains paramount and often obligatory, there has been a notable surge of interest in circulating biomarkers over the years given the numerous benefits associated with liquid biopsies. Currently, the clinic primarily relies on single-analyte assays such as the chromogranin A assay, but these are far from ideal because of limitations such as compromised sensitivity and specificity as well as a lack of standardization. Consequently, the quest for NEN biomarkers continued with the exploration of multianalyte markers, exemplified by the development of the NETest and ctDNA-based analysis. Here, an extensive panel of markers is simultaneously evaluated to identify distinct signatures that could enhance the accuracy of patient diagnosis, prognosis determination, and response to therapy prediction and monitoring. Given the promising results, the development and implementation of these multianalyte markers are expected to usher in a new era of NEN biomarkers in the clinic. In this review, we will outline both clinically implemented and more experimental circulating markers to provide an update on developments in this rapidly evolving field.Keywords
Funding Information
- Research Foundation Flanders (1S94923N, 1803723N)
This publication has 108 references indexed in Scilit:
- The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in BloodPLOS ONE, 2013
- Circulating Tumor Cells As Prognostic Markers in Neuroendocrine TumorsJournal of Clinical Oncology, 2013
- Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumorsScandinavian Journal of Gastroenterology, 2012
- Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?European Journal of Cancer, 2012
- Risk Factors for the Development and Progression of Carcinoid Heart DiseaseThe American Journal of Cardiology, 2011
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- Circulating Tumor Cells and EpCAM Expression in Neuroendocrine TumorsClinical Cancer Research, 2011
- The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine TumorsPancreas, 2010
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II TrialJournal of Clinical Oncology, 2010
- Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: Value of measurement in diagnosis and treatmentDigestive Diseases and Sciences, 1978